Phil Burke to Present “Best Practices” for Device Development with Drug/Device Combination Products at Boston Summit.
Combination products integrate a medical device for the delivery of a therapeutic drug. Examples can be as straightforward as an auto-injector pen and as sophisticated as interventional devices designed to deliver a precise dose of a therapeutic deep within the body. It is a large and growing segment within healthcare, with global sales projected to reach $267 billion by 2027.
“Rev.1 has a strong track record of developing sophisticated, interventional devices, including combination products,” said Eric Johnson, co-founder and CEO of Rev.1 Engineering. “Our experience developing devices for highly critical, often life-saving procedures has prepared us well for the coming wave of complex technologies.”
Over the past decade, Rev.1 Engineering has developed more than 140 devices for 70 companies. It’s also not uncommon for Rev.1 clients to be acquired by large, multi-national companies such as Medtronic, St. Jude Medical and Abbott.
“Early on, we adopted a highly disciplined approach to program management, compliance and documentation,” commented Phil Burke, co-founder and COO of Rev.1. “This has proven to be very fortuitous, especially when it comes to developing combination products. The parallel, regulatory path the drug and device components must individually follow benefits significantly from our approach. This meticulous process scrubs risk away from the project while simultaneously accelerating the path to commercialization.”
“At the end of the day, it’s our team that really sets us apart,” added Eric. “Our engineers have an average of more than 20 years experience designing and developing interventional devices that consistently push the technological envelope.”
The Combination Products Life Cycle Summit is being held at the Boston Hilton Back Bay, June 19th – 21st.